 |
|
Hypogonadism and Osteoporosis in Men—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We would like to respond to the thoughtful comments of Dr Mikhail. For the most part, we believe the apparent disagreement (ie, testosterone as a treatment for osteoporosis in men) expressed by Mikhail has more to do with semantics than substance. We agree that hypogonadal elderly men with osteoporosis likely will benefit from treatment with exogenous testosterone. However, in our study,1 in which we determined the number of men and women with hip fractures who were treated for osteoporosis, we tallied patients who were taking calcium and vitamin D only, patients taking a Food and Drug Administration–approved antiresorptive agent for the treatment and/or prevention of osteoporosis (namely, estrogen, calcitonin, raloxifene, alendronate, risedronate), and patients taking both calcium and vitamin D and an antiresorptive agent. Testosterone is not approved by the Food and Drug Administration for the treatment or prevention of osteoporosis. No studies have shown that testosterone decreases . . . [Full Text of this Article]
RELATED ARTICLES
Hypogonadism and Osteoporosis in Men
Nasser Mikhail
Arch Intern Med. 2003;163(10):1237.
EXTRACT
| FULL TEXT
Undertreatment of Osteoporosis in Men With Hip Fracture
Gary M. Kiebzak, Garth A. Beinart, Karen Perser, Catherine G. Ambrose, Sherwin J. Siff, and Michael H. Heggeness
Arch Intern Med. 2002;162(19):2217-2222.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Fractures, Osteoporosis, and the Endocrinologist
Field
Arch Intern Med 2003;163:2796-2796.
FULL TEXT
|
